Accelerated programme to provide point-of-care molecular diagnostic test for SARS-CoV-2
Sense Biodetection has announced an accelerated programme to launch the world’s first instrument-free, point-of-care molecular diagnostic test for SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. Sense is partnering closely with Phillips-Medisize to scale-up production of its test in order to meet the growing demand for rapid diagnostics.
Sense’s Veros SARS-CoV-2 is a simple disposable test that uses a nasal swab sample to give an ultra-rapid result without the need for instrumentation. As a molecular test, its performance is equivalent to gold-standard laboratory tests, but it is easy to use in any setting and results are available in under 10 minutes. The test is fully self-contained and can be distributed widely to wherever it is needed, overcoming the logistical and contamination problems associated with machine-based testing.
Other News
Featured Supplier
Verulam Scientific Ltd is an analytical instrument company providing innovative solutions and emerging technologies to the UK pharmaceutical, environmental, life science, food, clinical and biotechnology markets. We provide laboratories with the equipment and services that are crucial to modern analytical services and research.
Upcoming Events
Every Minute Counts: a SHOT, BBTS and NBTC joint webinar
Online
3 December 2021
IBMS Biomedical Science Congress 2022
International Convention Centre, Birmingham
14-17 March 2022
Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.
Download the FREE Pathology In Practice app from your device's App store
